Extended Specialized Assertive Intervention for First Episode Psychosis
NCT00914238 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 400
Last updated 2016-10-25
Summary
In a randomized clinical trial, the researchers want to investigate if the positive short-term outcomes (first 1-2 years), achieved with specialized assertive intervention programme (OPUS), can be maintained for five years if the specialized treatment is sustained over the first five years in comparison to only two years of specialized treatment followed by three years of standard treatment.
Conditions
- First Episode Psychosis of Schizophrenia and Schizotypal Disorder
- Psychotic Disorders
- Schizophrenia
- Schizoaffective Disorder
Interventions
- BEHAVIORAL
-
2 years OPUS treatment
2 years OPUS and transfer to standard treatment.
- BEHAVIORAL
-
OPUS 5 years
Sponsors & Collaborators
-
Mental Health Services in the Capital Region, Denmark
collaborator OTHER -
Region Capital Denmark
collaborator OTHER - collaborator OTHER_GOV
-
Aarhus University Hospital
collaborator OTHER -
University of Copenhagen
lead OTHER
Principal Investigators
-
Merete Nordentoft, Professor · University of Copenhagen
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 37 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2009-07-31
- Primary Completion
- 2015-06-30
- Completion
- 2016-10-31
Countries
- Denmark
Study Locations
More Related Trials
-
Fluoxetine vs Aripiprazole Comparative Trial (FACT)
NCT02357849 ·Status: TERMINATED ·Phase: PHASE4
-
Effectiveness and Safety of Atypical Antipsychotic Agents in Augmenting SSRI-Refractory Obsessive-Compulsive Disorder
NCT00854919 ·Status: COMPLETED ·Phase: PHASE4
-
The Role of Antidepressants or Antipsychotics in Preventing Psychosis
NCT01724372 ·Status: WITHDRAWN ·Phase: NA
-
A Study to Assess the Safety and Efficacy of ASP4345 as Add-on Treatment for Cognitive Impairment in Subjects With Schizophrenia on Stable Doses of Antipsychotic Medication
NCT03557931 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy & Safety Study of Oral Aripiprazole in Adolescents With Schizophrenia
NCT01149655 ·Status: COMPLETED ·Phase: PHASE3
-
Effectiveness of Atypical Versus Conventional Antipsychotics in Treating Schizophrenia
NCT00237861 ·Status: COMPLETED ·Phase: PHASE4
-
Optimizing Response in Psychosis Study
NCT00314327 ·Status: TERMINATED ·Phase: PHASE4
-
A Study of Extended Release Extended-release (ER) OROS Paliperidone Tolerability, as Compared to Immediate-release (IR)Risperidone, in Patients With Schizophrenia
NCT00791232 ·Status: COMPLETED ·Phase: PHASE1
-
Pan European Collaboration on Antipsychotic Naïve Schizophrenia II
NCT02339844 ·Status: COMPLETED ·Phase: PHASE4
-
An Efficacy, Safety And Tolerability Study of Flexibly Dosed Paliperidone Extended Release (ER) in Participants With Schizophrenia
NCT00460512 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Aripiprazole in Patients With Schizophrenia in General Psychiatric Practices
NCT00292409 ·Status: COMPLETED ·Phase: PHASE3
-
10-year Follow-up of Clinical Outcome After Antipsychotic Treatment Discontinuation in Psychosis Individuals
NCT03090490 ·Status: UNKNOWN ·Phase: NA
-
Efficacy and Safety of Aripiprazole in First Episode Psychosis
NCT01026584 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy Study of Paliperidone to Evaluate Subjective Change in Well-being and Drug Attitude in Schizophrenic Participants
NCT00784238 ·Status: COMPLETED ·Phase: PHASE4
-
A Study of Mifepristone vs. Placebo in the Treatment of Patients With Major Depression With Psychotic Features
NCT00637494 ·Status: TERMINATED ·Phase: PHASE3
-
Antipsychotic to Treat Psychosis Syndrome
NCT02137616 ·Status: UNKNOWN ·Phase: NA
-
Aripiprazole in the Treatment of Patients With Schizophrenia and Symptoms of Obsessive Compulsive Disorder (OCD)
NCT00374348 ·Status: COMPLETED ·Phase: NA
-
An Efficacy, Safety And Tolerability Study of Flexibly Dosed Paliperidone Extended-Release (ER) in Participants With Schizophrenia
NCT00757705 ·Status: COMPLETED ·Phase: PHASE4
-
Schizophrenia Trial of Aripiprazole
NCT00237913 ·Status: COMPLETED ·Phase: PHASE3
-
Substance Misuse To Psychosis for Stimulants
NCT03485417 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Study Comparing Antipsychotic Dose Reduction vs. Maintenance Treatment in Patients With Schizophrenia Spectrum Disorder: a Personalized Medicine Approach
NCT07152184 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
A Follow-on Study of the Long-Term Safety of Aripiprazole in Patients With Chronic Schizophrenia
NCT02435836 ·Status: TERMINATED ·Phase: PHASE3
-
Standard Comprehensive Intervention to Treat First-episode Schizophrenia
NCT01057849 ·Status: UNKNOWN ·Phase: NA
-
Oral Versus Injectable Risperidone for Treating First-Episode Schizophrenia
NCT00330551 ·Status: COMPLETED ·Phase: PHASE4
-
Pragmatic RCT Comparing Aripiprazole, Olanzapine and Haloperidol in the Treatment of Schizophrenia
NCT01052389 ·Status: COMPLETED ·Phase: PHASE4